Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI

Beisheng Yang1†‡, Chunli Luo2†‡, Min Yu2, Lin Zhou2, Bo Tao1, Biqiu Tang1, Ying Zhou3, Jiang Zhu3, Meijuan Huang3, Feng Peng3, Yongmei Liu3, Yong Xu2, Yan Zhang4, Xiaojuan Zhou4, Jianxin Xue4, Yanying Li2, Yongsheng Wang3, Zhiping Li4, You Lu2, Su Lui1 and Youling Gong2*

1 Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital of Sichuan University, Chengdu, China, 2 Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 3 Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 4 Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China

*Correspondence:
Youling Gong
drgongyouling@hotmail.com

†Present address:
Beisheng Yang, Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
Chunli Luo, Department of Medical Oncology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China

‡These authors have contributed equally to this work

Specialty section:
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology

Received: 08 July 2020
Accepted: 20 November 2020
Published: 06 January 2021

Citation:
Yang B, Luo C, Yu M, Zhou L, Tao B, Tang B, Zhou Y, Zhu J, Huang M, Peng F, Liu Y, Xu Y, Zhang Y, Zhou X, Xue J, Li Y, Wang Y, Li Z, Lu Y, Lui S and Gong Y (2021) Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI. Front. Oncol. 10:573512. doi: 10.3389/fonc.2020.573512

Purpose: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy is the routine treatment for patients with metastatic non-small cell lung cancer (NSCLC) harboring positive EGFR mutations. Patients who undergo such treatment have reported cognitive decline during follow-up. This study, therefore, aimed to evaluate brain structural changes in patients receiving EGFR-TKI to increase understanding of this potential symptom.

Method: The medical records of 75 patients with metastatic NSCLC (without brain metastasis or other co-morbidities) who received EGFR-TKI therapy from 2010 to 2017 were reviewed. The modified Scheltens Visual Scale and voxel-based morphometry were used to evaluate changes in white matter lesions (WML) and gray matter volume (GMV), respectively.

Results: The WML scores were higher at the 12-month [8.65 ± 3.86; 95% confidence interval (CI), 1.60–2.35; p < 0.001] and 24-month follow-ups (10.11 ± 3.85; 95% CI, 2.98–3.87; p < 0.001) compared to baseline (6.68 ± 3.64). At the 24-month follow-up, the visual scores were also significantly higher in younger patients (3.89 ± 2.04) than in older patients (3.00 ± 1.78; p = 0.047) and higher in female patients (3.80 ± 2.04) than in male patients (2.73 ± 1.56; p = 0.023). Additionally, significant GMV loss was observed in sub-regions of the right occipital lobe (76.71 voxels; 95% CI, 40.740–112.69 voxels), left occipital lobe (93.48 voxels; 95% CI, 37.48–149.47 voxels), and left basal ganglia (37.57 voxels; 95% CI, 21.58–53.57 voxels) (all p < 0.005; cluster-level false discovery rate < 0.05).

Conclusions: An increase in WMLs and loss of GMV were observed in patients with metastatic NSCLC undergoing long-term EGFR-TKI treatment. This might reflect an unknown side-effect of EGFR-TKI treatment. Further prospective studies are necessary to confirm our findings.

Keywords: non-small cell lung cancer, epidermal growth factor receptor-tyrosine kinase inhibitor, white matter lesion, gray matter, MRI
INTRODUCTION

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. About 40–50% of Asian patients with NSCLC harbor epidermal growth factor receptor (EGFR) mutations, and distant metastases are observed in nearly 40% of these patients at initial diagnosis (1). The approval of gefitinib, the first-generation EGFR tyrosine kinase inhibitor (TKI), led to the development of molecular targeted therapy for lung cancer (2). Prospective phase III trials have established that EGFR-TKIs are superior to chemotherapy for patients harboring an EGFR mutation (3–6). Therefore, EGFR-TKIs have been recommended as first-line treatment for such patients in clinical guidelines (7, 8). Consequently, EGFR-TKI therapy has been routinely prescribed for patients with EGFR mutations worldwide.

The known side effects of targeted therapy with EGFR-TKIs include rashes, diarrhea, hepatic impairment, mucositis, and interstitial pneumonia (9). However, during routine follow-ups, patients with NSCLC undergoing EGFR-TKI treatment in our department, the Oncology Department of West-China Hospital, have reported cognitive decline after starting EGFR-TKI treatment, a side effect that has not previously been reported. Meanwhile, a recent study evaluated the neuropsychological performance of patients with NSCLC who underwent targeted therapy and reported that depression and/or anxiety were correlated with the treatment, but details regarding drug utilization in this study were not clear (10). Potential reasons for these neuropsychiatric symptoms remain unknown.

Many studies have reported that epidermal growth factor (EGF) is involved in the main biological pathway of neurodevelopment and repair of nerve injury by promoting the proliferation, regeneration, and development of neurons (11–13). Thus, the inhibition of the EGF pathway caused by EGFR-TKIs could negatively influence the differentiation, maturation, and rehabilitation of neural cells, which may lead to chronic cognitive function impairments. In this context, exploring structural changes in patients’ brains before and after EGFR-TKI treatment could help in determining the causes of cognitive decline.

It has been reported that white matter lesions (WMLs) are an indication of cognitive impairment, especially in the elderly and patients with specific comorbidities (14, 15). The loss of gray matter volume (GMV) has also been associated with mild cognitive impairment, including memory loss and attention and language dysfunction (16, 17). MRI-based studies have confirmed that WMLs and gray matter atrophy (GMA) could be the primary imaging correlates of early dementia and mild cognitive impairment in several chronic diseases, including Parkinson’s disease, diabetes mellitus, and Alzheimer’s disease, among others (18–20).

Patients with metastatic NSCLC who undergo EGFR-TKI treatment at our hospital receive routine MRIs. This allowed us to investigate the potential impact of long-term EGFR-TKI therapy on patients’ brains, which has not yet been evaluated. Thus, for the first time, we collected brain MRI images of patients with NSCLC to investigate changes in WMLs and GMV.

MATERIALS AND METHODS

This retrospective study was approved by the ethics committee at West China Hospital, Sichuan University and was in full accordance with the International Conference of Harmonization Good Clinical Practice Guidelines. Informed consent was obtained during follow-up, and for those who were lost to follow-up (e.g., death, emigration), we were granted permission by the ethics committee at West China Hospital, Sichuan University for an informed consent waiver.

Patients with pathologically-confirmed metastatic NSCLC between 2010 and 2017 in West China Hospital, Sichuan University were included. The inclusion criteria were as follows: a) positive for EGFR mutation (19 exon deletion or 21 exon L858R mutation detected by amplification refractory mutation system, differential display-polymerase chain reaction, or next generation sequencing), b) received first-generation EGFR-TKIs (gefitinib, erlotinib, or icotinib, according to the Chinese Food and Drug Administration’s approval); and c) brain MRI data available during follow-up at our hospital. Exclusion criteria were as follows: a) suffering from a neurological or psychiatric disease; b) presence of comorbidities that might influence the patient’s brain structure (e.g., type 2 diabetes, hypertension, chronic kidney disease); c) identification of brain metastases during MRI at baseline or anytime during the evaluation period; d) substantial abuse including alcohol or narcotics; and e) any other concurrent systematic therapy (e.g., chemotherapy, anti-angiogenetic therapy, or immunotherapy).

Treatment and Follow-Up

After EGFR-TKI treatment initiation, objective assessments of all the eligible patients were recorded every 3 months according to the RESIST criteria (21). The patients underwent a brain MRI every 6 months when no neural symptoms or physical signs were observed; otherwise, a brain MRI was performed immediately to rule-out brain metastasis. The EGFR-TKI dose was modified according to the instructions specific to each drug. The duration of the follow-up period was ≥ 24 months.

Image Acquisition

Image data were retrospectively collected from our hospital’s PACS (Picture Archiving and Communication System). Since there are multiple MRI scanners at our hospital, T2-FLAIR (fluid attenuated inversion recovery) images for WML assessments were acquired using different scanners from two different manufacturers (GE and Siemens) and with varying magnetic field intensities (1.5-T, n = 154 person-time; and 3.0-T, n = 82 person-time). Since the WML diagnostic features were high signal spots in the T2-FLAIR sequence, the evaluation of visual scores were not affected by the different scanners. A high resolution T1WI (1.0 mm/slice) MRI was not routinely used for all the patients due to its extra charge;

Abbreviations: EGFR-TKI, Epidermal growth factor receptor-tyrosine kinase inhibitor; NSCLC, Non-small cell lung cancer; WML, white matter lesion; GMV, gray matter volume; MRI, magnetic resonance imaging; GMA, gray matter atrophy; VBM, voxel-based morphometry; FDR, false discovery rate; FLAIR, fluid attenuated inversion recovery.
however, we screened the image data for available high resolution T1WI MRIs before and after about 1-year treatment, which were obtained by the same 3.0 T MRI system. The images of 21 patients (13 by Siemens scanners; 8 by GE scanners) were determined to be suitable for GMV analysis.

Definitions and Acquisition of White Matter Lesion and Gray Matter Volume

WMLs are regions of white matter that have an abnormal white matter fiber tract, which present as hyperintense regions on MRI T2-FLAIR sequence images with different shapes categorized as: periventricular caps, rims, or halos; subcortical multiple punctuates or patchy lesions; and partially or completely confluent lesions. They are often divided into two broad categories, namely, periventricular WMLs (attached to the ventricular system) and deep WMLs (located at the subcortical white matter area) (22, 23).

WMLs from axial T2-FLAIR images were evaluated using the modified Scheltens Visual Scale (SVS; Supplementary Material, Section A), with which periventricular and white matter hyperintensities are semi-quantitatively rated. The modified SVS is used to rate WMLs in the periventricular region on a 7-point scale (0–6) and those in the subcortical region on a 25-point scale (0–24) according to the size and number of lesions (24, 25). The modified SVS was used to evaluate the WMLs seen on T2-FLAIR images at baseline and after 12 months and 24 months of EGFR-TKI therapy (one representative patient is shown in Supplementary Material, Section B).

Gray matter is a major component of brain parenchyma and consists of neuronal cell bodies, neuropils (dendrites and axons), glial cells, and capillaries. It is distinguished from white matter in that it contains numerous neuronal cell bodies and relatively few myelinated axons. GMV is determined using optimized voxel-based morphometry (VBM) (26), a computational neuroanatomy method that measures the number of voxels of gray matter after separating them from white matter using T1WI.

In this study, the GMV analysis was performed using the Statistical Parametric Mapping Package (SPM8) (http://www.fil.ion.ucl.ac.uk/spm/), with the VBM-based diffeomorphic anatomical registration using the exponentiated lie algebra (VBM-DARTEL) toolbox (27). First, the high-resolution images of all the patients before and after treatment were segmented into gray matter, white matter, and cerebrospinal fluid. Second, the segmented gray matter was smoothed to create the primary DARTEL template. After 18 iterative operations with raw segmented gray matter images, six templates were created and the sixth template, which is considered to have maximum accuracy and sensitivity (28), was registered to the Montreal Neurological Institute space. All the patients’ GMVs before and after treatment were obtained for further statistical analysis.

Statistical Analysis

The normality of the WML SVS scores was tested using the Shapiro-Wilk test. Paired sample t-tests were used to test differences in the WML scores before and after treatment. Independent sample t-tests were used to evaluate variations in WMLs from baseline according to sex, age, type of mutation, and type of TKI therapy.

Changes in GMV before and after EGFR-TKI therapy were tested using paired sample t-tests (uncorrected p value < 0.001), and corrected using a false discovery rate (FDR) of p < 0.05 at cluster level and peak level. A cluster level test takes into account the size of the cluster that consists of adjacent voxels as test objects, and a cluster size above the voxel’s threshold has a statistical significance suitable for small samples. For the peak level test, each voxel is regarded as an independent test subject, meaning a much stricter FDR is required for viability.

RESULTS

Patient Characteristics

The median age of all 75 patients with NSCLC was 60 years (range, 38–71 years) and the majority were women (49/75, 65.3%). Forty-one (54.7%) and 34 (45.3%) patients were positive for EGFR 19 exon deletion and 21 exon L858R transformation, respectively. The median duration of intracranial progression-free survival was 32.0 months (range, 23.0–89.0 months). For the 21 patients included in the GMV analysis, the median age was 59 years (range, 43–70 years) and the majority were female (12/21, 57.1%) (Table 1).

Changes in White Matter Lesions

The SVS scores of the WMLs at baseline varied between 0 and 17.00, and increased at the 12-month and 24-month follow-ups (Figure 1A). Compared to baseline (6.68 ± 3.64), the scores were significantly higher at the 12-month [8.65 ± 3.86; 95% confidence interval (CI) 1.56–2.35, p < 0.001] and 24-month (10.11 ± 3.85; 95% CI 2.98–3.87, p < 0.001) follow-ups (Figure 1B).

Sub-group analyses showed that the SVS scores at baseline were significantly higher in older patients (> 60 years) than in younger patients (≤ 60 years) (7.62 ± 3.56 vs. 5.67 ± 3.49, respectively; p = 0.019). Compared to older patients, the younger patients also showed significantly higher SVS scores at the 24-month follow-up.

| TABLE 1 | Baseline characteristics of patients present study. |
|-------------------|-------------------|-------------------|
| **Baseline characteristics** | **Patients for WML analysis, number** | **Patients for GMV analysis, number** |
| Age (years) | 60 (range of 38–71) | 59 (range of 43–70) |
| Sex (%) | | |
| Male | 26 (54.7) | 9 (42.9) |
| Female | 49 (65.3) | 12 (57.1) |
| ECOG performance status (%) | | |
| 0 | 38 (50.7) | 10 (47.6) |
| 1 | 37 (49.3) | 11 (52.4) |
| EGFR mutation (%) | | |
| 19 del | 41 (54.7) | 12 (57.1) |
| 21L858R | 34 (45.3) | 9 (42.9) |
| EGFR-TKI (%) | | |
| Gefitinib | 30 (40) | 13 (61.9) |
| non-Gefitinib | 45 (60) | 8 (38.1) |
| Progression-free survival (months) | 32 (range of 23–89) |

Data are median (IQR) or number (%); ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
up (3.00 ± 1.78 vs. 3.89 ± 2.04, respectively; p = 0.047) but not at the 12-month (2.19 ± 1.69 vs. 1.77 ± 1.56, respectively; p = 0.266) follow-up (Figure 1C). For the SVS scores at baseline, no significant differences were found between female and male patients (6.27 ± 3.37 vs. 7.46 ± 4.05, respectively; p = 0.177). However, SVS scores were significantly higher for female patients than male patients at the 12-month (2.31 ± 1.66 vs. 1.35 ± 1.44, respectively; p = 0.015) and 24-month (3.80 ± 2.04 vs. 2.73 ± 1.56, respectively; p = 0.023) follow-ups (Figure 1D). No significant differences in SVS scores were observed according to the different EGFR mutation types or EGFR-TKIs the patients receiving.
Changes in Gray Matter Volume

The total GMV of patients was $673.8 \pm 58.5$ cm$^3$ and $667.6 \pm 60.3$ cm$^3$ at baseline and the 12-month follow-up, respectively. Uncorrected GMV loss ($p < 0.001$) was identified in brain MRIs (Figure 2). The total voxel values were clearly lower after EGFR-TKI treatment than at baseline in three main clusters: the sub-regions of the middle and inferior occipital cortex (1,697 voxels); the right middle and inferior occipital cortex extending to the lingual gyrus and entorhinal cortex (1,660 voxels); and the left lentiform nucleus, which included the putamen and pallidum (1,145 voxels) (Table 2). Mild GMV loss was observed in the left precentral gyrus, which included part of Brodmann area 6 (321 voxels); two independent clusters at the right lentiform nucleus (142 and 125 voxels), both of which included parts of the putamen and pallidum; and the right insula extending to the superior temporal gyrus (269 voxels).

After the cluster-level FDR was corrected to $p < 0.05$, significant GMV loss remained in three main clusters: the right middle and inferior occipital cortex extending to the lingual and entorhinal gyrus, the left lentiform nucleus, and the middle and
inferior occipital cortex (p = 0.012, p = 0.003, and p = 0.003, respectively) (Table 3, Figure 3). The peak-level FDR-corrected analysis showed no significant difference between GMV atrophies at baseline and the 12-month follow-up in these three main clusters (p = 0.054, p = 0.653, and p = 0.885, respectively). The other four clusters were not significant after cluster-level or peak-level FDR correction (all p > 0.05).

**DISCUSSION**

Previous studies have revealed that the most common adverse effects of EGFR-TKI therapy are skin rashes (31.4%), diarrhea (14.2%), pruritus (6.7%), and hepatic toxicity (3.8%) (9). For the first time, using a series of brain MRIs, significant worsening of WMLs and GMA were observed among patients with advanced-stage NSCLC receiving long-term EGFR-TKI treatment.

The existing literature suggests that EGF is expressed in the cortical plate during neural development, promoting the neurite outgrowth of cortical neurons (11), and the EGFR pathway is linked to multiple nerve cell events, such as proliferation, differentiation, and apoptosis (12). Recently, an EGFR pathway-regulating compound (yhuu-3792) was reported to induce cognitive impairment in mice by inhibiting neural pathways in the hippocampus (29). This microvascular anomaly is believed to be one of the principle causes of WMLs, as EGFR and vascular EGF pathways are closely related and share common downstream signaling pathways (30). Therefore, long-term EGFR-TKI therapy could potentially induce WMLs and GMA.

GMA and WMLs are reportedly associated with a rapid or excessive decline in global cognitive performance, executive function, and processing efficiency (17, 31, 32). Furthermore, structural changes in the brain are strongly correlated with a patient’s cognitive status (17, 33, 34). In the present study, the reduction in gray matter was nearly 0.92% after 12 months of EGFR-TKI treatment, while a large cross-sectional study (479 healthy participants) using SPM8 to measure age-related changes in GMV reported a global loss of 0.57% per year (35). Even though directly comparing these two studies is not sufficient evidence, it may be used to some extent to demonstrate the difference between patients receiving EGFR-TKI therapy and healthy people, especially given the difficulty in collecting longitudinal image data of healthy people along aging. Physical frailty-related GMV loss has been observed in the bilateral frontal and occipital cortices, while cognitive impairment-related GMV loss has been observed in the bilateral frontal, occipital, and temporal cortices (17). Similarly, we observed significant GMV loss mainly in sub-regions of the bilateral occipital lobes and the left basal ganglia. Unfortunately, no cognitive function tests (e.g., Wechsler adult intelligence scale-III, mini-mental state examination, color trails test, etc.) were performed on the patients who received EGFR-TKI treatment at baseline or during follow-up. We could not, therefore, analyze possible cognitive impairments caused by the changes in brain structure in the patients.

Previous studies on healthy elderly populations have reported either no significant progression of WMLs associated with age (36), or a mild increase of 0.2 to 0.4% per year (37). In this study, however, we observed significant deterioration of WMLs in patients with NSCLC who received EGFR-TKI therapy. The baseline WML score was significantly higher in older patients than in younger patients (p = 0.019), which is in accordance with recent reported findings (14, 22). At the 24-month follow-up, however, the WML scores

**TABLE 2 |** Sub-regions with GMV atrophy of patients treated with EGFR-TKIs.

| Cluster | Total voxels | Region1 | Voxels | Region2 | Voxels | Region3 | Voxels |
|---------|--------------|---------|--------|---------|--------|---------|--------|
| 1       | 1697         | Occipital_Mid_L | 1153   | Occipital_Mid_L | 377   | –       | –      |
| 2       | 1680         | Occipital_Inf_R | 705    | Occipital_Mid_R | 573   | Fusiform_R | 247   |
| 3       | 1145         | Lentiform Nucleus_L | 782    | Putamen_L | 604   | Pallidum_L | 174   |
| 4       | 321          | Precentral Gyrus_L | 211    | Brodman area 6 | 96    | –       | –      |
| 5       | 269          | Insula_R | 109    | Temporal_Sup_R | 84    | –       | –      |
| 6       | 142          | Lentiform Nucleus_R | 115    | Putamen_R | 106   | Pallidum_R | 9     |
| 7       | 125          | Lentiform Nucleus_R | 123    | Putamen_R | 79    | Pallidum_R | 45    |

GMV, gray matter volume.

**TABLE 3 |** Statistic information of sub-regions with GMV reduction in patients treated with EGFR-TKIs.

| Cluster | Equivk | p (uncorr) | p (FDR-corr) | T | p (uncorr) | p (FDR-corr) | X (mm) | Y (mm) | Z (mm) |
|---------|--------|------------|--------------|---|------------|--------------|--------|--------|--------|
| 1       | 1145   | 0.001      | 0.012        | 6.88 | 0.000 | 0.054 | –29 | –17 | –2 |
| 2       | 1660   | 0.000      | 0.003        | 4.84 | 0.000 | 0.663 | 35 | –86 | –11 |
| 3       | 1697   | 0.000      | 0.003        | 3.78 | 0.001 | 0.885 | –39 | –83 | 0 |
| 4       | 321    | 0.06       | 0.387        | 3.83 | 0.001 | 0.885 | –44 | –12 | 65 |
| 5       | 142    | 0.194      | 0.825        | 4.09 | 0.000 | 0.885 | 29 | –18 | 5 |
| 6       | 125    | 0.222      | 0.825        | 3.69 | 0.001 | 0.885 | 26 | –5 | 2 |
| 7       | 269    | 0.082      | 0.424        | 3.50 | 0.001 | 0.885 | 41 | –33 | 17 |

GMV, gray matter volume; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; Equivk, equivalent voxels k; Corr, corrected; FDR, false discovery rate; X, Y, Z, x,y and z axis, respectively.
were significantly higher in younger patients than older ones \( (p = 0.047) \), indicating that the younger patients were more sensitive to therapy. This could be explained by the higher proliferation rate of neural stem and progenitor cells in younger compared to older people, leading to a higher chance they would be affected by EGFR-TKI therapy. Women reportedly have significantly more WMLs relative to white matter volume than men \((2.8\% \text{ vs. } 2.4\%, \text{ respectively; } p < 0.001)\) \( (38) \), and a greater marked progression of subcortical WML and incident lacunar infarcts than men \( (39) \). Similarly, the changes in WML scores in this study were more significant in female patients than in male patients at the 12-month and 24-month follow-ups. However, there were no significant differences in WML scores based on the type of EGFR mutation or EGFR-TKI therapy received.

For dementia research, visual rating scores from routine brain MRIs, which are recognized as a practical and inexpensive way to improve diagnostic accuracy, are recommended for assessing cognitive impairment. Prior to the application of more advanced image analysis techniques in clinical practice, visual rating scales were widely used and recommended for evaluating patients clinically with suspected dementia and was considered a diagnostic criterion for numerous types of dementia \( (22, 23, 40) \). Compared to several other visual rating scales, including the Fazekas scale \( (41) \), Rotterdam Scan Study (RSS) scale \( (37) \), modified SVS \( (24) \), Koedam posterior atrophy (PA) scale \( (42) \), and Prins scale \( (25) \), which were developed specifically to rate the vulnerability of brain regions to atrophy in different types of dementias, the SVS has been recommended for observing longitudinal changes in WMLs for chronic diseases and their relationship to clinical variables \( (43-45) \). GMV changes have been evaluated using the VBM-toolbox on SPM8, and the reliability of extracting quantitative brain metrics, such as GMV,
in clinical-quality MRIs has been justified (46). Uncorrected voxel-based statistics increase the sensitivity as FDR increases (28). In this study, the FDR-corrected analysis was performed to minimize bias. Thus, the theoretical foundation and MRI analysis performed in the present study were relatively robust and have been validated by a large number of studies worldwide.

However, this study also had some limitations. First, the retrospective nature and relatively limited sample size of this study restricts its value in routine practice. Additionally, since a cognitive analysis was not conducted, interpreting the potential relationship between changes in the brain structure and cognition could not be assessed, even though significant worsening of the brain structure was observed. Second, data on mental status (depression or anxiety) before and during follow-up were not available, and subtle mental symptoms are difficult for patients to detect themselves. However, concomitant neuropsychiatric symptoms, such as depression or anxiety, in patients with NSCLC who undergo target therapy may exist, as reported previously (10). Third, systemic chemotherapy might have affected patients’ cognitive function (47, 48). Previous evaluations of cognition and brain structure changes in patients with lung cancer have demonstrated cognitive impairments after chemotherapy (49). Consequently, patients with lung cancer who undergo chemotherapy could not be used as controls. Additionally, no healthy volunteers were analyzed as controls in this retrospective setting. Therefore, the brain alterations observed in the present study should be interpreted cautiously unless they are validated by prospective data sets.

**CONCLUSION**

This retrospective structural analysis of a series of brain MRIs showed significant worsening of WMLs and GMA in patients with advanced-stage NSCLC undergoing chronic EGFR-TKI treatment, which may indicate that this could be an unknown side-effect of EGFR-TKI treatment. Further prospective studies are being designed to more definitively determine the effects of long-term EGFR-TKI treatment on cognitive ability.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the ethics committee of West China Hospital, Sichuan University. The patients/participants provided their written informed consent to participate in this study. For patients were lost to follow-up (e.g., death, emigration), the informed consent waiver was permitted by the ethics committee at West China Hospital, Sichuan University.

**AUTHOR CONTRIBUTIONS**

YG conceived and designed the study. BY, CL, and YG collected, analyzed, and interpreted the data and drafted the article. BoT and BiT contributed to the evaluation of WML. MY, LZ, YiZ, JZ, MH, FP, YoL, YX, YaZ, XZ, JX, YaL, YW, ZL, YouL, and SL interpreted the data and revised the paper critically. All authors contributed to the article and approved the submitted version.

**FUNDING**

This project was supported by grants from Sichuan Provincial Science and Technology Funding to YG (2018SZ0184) and LZ (2019YFS0323), and National Natural Science Foundation to LZ (81872466).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fonc.2020.573512/full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fonc.2020.573512/full#supplementary-material)

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin (2018) 68:7–30. doi: 10.3322/caac.21442
2. Ciardiello F, Tortora G. A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor. Clin Cancer Res (2001) 7:2958.
3. Hollien MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. *Onco Targets Ther* (2019) 12:1413–21. doi: 10.2147/OTT.S189438
4. Loong HH, Kwan SS, Mok TS, Lau YM. Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. *Curr Treat Options Oncol* (2018) 19:58. doi: 10.1007/s11864-018-0570-9
5. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. *J Thorac Oncol* (2016) 11:946–63. doi: 10.1016/j.jtho.2016.05.008
6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* (2012) 13:239–46. doi: 10.1016/S1470-2045(11)70393-X
7. David S, Ettinger DEW, Aggarwal C. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer NCCN guidelines Version 4. National Comprehensive Cancer Network (2019).
8. Wu YI, Planchar D, Lu S, Sun H, Yamamoto N, Kim DW, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SOS and TOS. *Ann Oncol* (2019) 30:171–210. doi: 10.1093/annonc/mdy554
9. Shah RR, Shah DR. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. *Drug Saf* (2019) 42:181–98. doi: 10.1007/s40264-018-0772-2

---

Yang et al. Structural Brain Changes After EGFR-TKI Therapy

---
46. Adduru VR, Michael AM, Helguera M, Baum SA, Moore GJ. Leveraging Clinical Imaging Archives for Radiomics: Reliability of Automated Methods for Brain Volume Measurement. *Radiology* (2017) 284:862–9. doi: 10.1148/radiol.2017161928

47. Matsos A, Johnston IN. Chemotherapy-induced cognitive impairments: A systematic review of the animal literature. *Neurosci Biobehav Rev* (2019) 102:382–99. doi: 10.1016/j.neubiorev.2019.05.001

48. Hermelink K, Buhner M, Sckopke P, Neufeld F, Kaste J, Voigt V, et al. Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. *J Natl Cancer Inst* (2017) 109(10): djx057. doi: 10.1093/jnci/djx057

49. Simó M, Root JC, Vaquero L, Ripollés P, Jové J, Ahles T, et al. Cognitive and brain structural changes in a lung cancer population. *J Thorac Oncol* (2015) 10:38–45. doi: 10.1097/JTO.0000000000000345

**Conflict of Interest:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer ZY declared a past co-authorship with one of the authors, SL, to the handling editor.

Copyright © 2021 Yang, Luo, Yu, Zhou, Tao, Tang, Zhou, Zhu, Huang, Peng, Liu, Xu, Zhang, Zhou, Xie, Li, Wang, Li, Lui and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.